Prescient Therapeutics Prospectus
Fully underwritten non renounceable pro rata entitlement offer of one New Share for every five Existing Shares and one New Option for every two New Shares issued at an offer price of $0.05 per New Share to raise approximately $2.1 million before the exercise of any New Options
Last date for acceptance and payment: 5.00pm (Sydney time) on 23 April 2019
If you are an Eligible Shareholder, this is an important document that requires your immediate attention. It should be read in its entirety. If, after reading this document, you have any questions about the securities being offered for issue under it or any other matter, you should contact your stockbroker, solicitor, accountant or other professional adviser.
This Prospectus also provides for the issue of the Placement Options on the terms announced by the Company on 25 March 2019.
THE ATTACHED DOCUMENT IS IMPORTANT AND SHOULD BE READ IN ITS ENTIRETY
Not for release to US wire services or distribution in the United States
View the Prospectus HERE
View the Letter to Eligible Shareholders Here
View the Letter to Ineligible Shareholders Here
View Letter to Option Holders Here
About Prescient Therapeutics (ASX: PTX, Prescient):
Prescient Therapeutics is developing drugs to treat a range of cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.
Exciting interim breast cancer data for PTX-200 has exhibited twice the effectiveness of standard therapy. A new transformative trial for PTX-100 will also soon commence.